COVID-19 Incidence During Delta and Omicron Variant Emergence

COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence

25 U.S. Jurisdictions, April 4-December 25, 2021

Amelia G. Johnson, DrPH; Avnika B. Amin, PhD; Akilah R. Ali, MPH; Brooke Hoots, PhD; Betsy L. Cadwell, PhD; Shivani Arora, MPH; Tigran Avoundjian, PhD; Abiola O. Awofeso, DVM; Jason Barnes, MBA; Nagla S. Bayoumi, DrPH; Katherine Busen, MPH; Carolyn Chang, MPH; Mike Cima, PhD; Molly Crockett, MPH; Alicia Cronquist, MPH; Sherri Davidson, PhD; Elizabeth Davis, MA; Janelle Delgadillo; Vajeera Dorabawila, PhD; Cherie Drenzek, DVM; Leah Eisenstein, MPH; Hannah E. Fast, MPH; Ashley Gent, MPH; Julie Hand, MSPH; Dina Hoefer, PhD; Corinne Holtzman, MPH; Amanda Jara, DVM; Amanda Jones, MPH; Ishrat Kamal-Ahmed, PhD; Sarah Kangas, MPH; FNU Kanishka, MPH; Ramandeep Kaur, PhD; Saadiah Khan, MPH; Justice King, MSc; Samantha Kirkendall, MS; Anna Klioueva, MPH; Anna Kocharian, MS; Frances Y. Kwon, MPH; Jacqueline Logan, MPH; B. Casey Lyons, MPH; Shelby Lyons, MPH; Andrea May, MPH; Donald McCormick, MSHI; Erica Mendoza, MAS; Lauren Milroy, MPH; Allison O'Donnell, MPH; Melissa Pike, MPH; Sargis Pogosjans, MPH; Amy Saupe, MPH; Jessica Sell, MPH; Elizabeth Smith, MPH; Daniel M. Sosin, MD; Emma Stanislawski, MPH; Molly K. Steele, PhD; Meagan Stephenson, MPH; Allen Stout, MS; Kyle Strand; Buddhi P. Tilakaratne, PhD; Kathryn Turner, PhD; Hailey Vest, MPH; Sydni Warner, MS; Caleb Wiedeman, MPH; Allison Zaldivar, MPH; Benjamin J. Silk, PhD; Heather M. Scobie, PhD

Disclosures

Morbidity and Mortality Weekly Report. 2022;71(4):132-138. 

In This Article

Abstract and Introduction

Introduction

Previous reports of COVID-19 case, hospitalization, and death rates by vaccination status indicate that vaccine protection against infection, as well as serious COVID-19 illness for some groups, declined with the emergence of the B.1.617.2 (Delta) variant of SARS-CoV-2, the virus that causes COVID-19, and waning of vaccine-induced immunity.[1–4] During August–November 2021, CDC recommended§ additional primary COVID-19 vaccine doses among immunocompromised persons and booster doses among persons aged ≥18 years.[5] The SARS-CoV-2 B.1.1.529 (Omicron) variant emerged in the United States during December 2021[6] and by December 25 accounted for 72% of sequenced lineages.[7] To assess the impact of full vaccination with additional and booster doses (booster doses),case and death rates and incidence rate ratios (IRRs) were estimated among unvaccinated and fully vaccinated adults by receipt of booster doses during pre-Delta (April–May 2021), Delta emergence (June 2021), Delta predominance (July–November 2021), and Omicron emergence (December 2021) periods in the United States. During 2021, averaged weekly, age-standardized case IRRs among unvaccinated persons compared with fully vaccinated persons decreased from 13.9 pre-Delta to 8.7 as Delta emerged, and to 5.1 during the period of Delta predominance. During October–November, unvaccinated persons had 13.9 and 53.2 times the risks for infection and COVID-19–associated death, respectively, compared with fully vaccinated persons who received booster doses, and 4.0 and 12.7 times the risks compared with fully vaccinated persons without booster doses. When the Omicron variant emerged during December 2021, case IRRs decreased to 4.9 for fully vaccinated persons with booster doses and 2.8 for those without booster doses, relative to October–November 2021. The highest impact of booster doses against infection and death compared with full vaccination without booster doses was recorded among persons aged 50–64 and ≥65 years. Eligible persons should stay up to date with COVID-19 vaccinations.

*These authors contributed equally to this report.
A COVID-19 case in a fully vaccinated person occurred when SARS-CoV-2 RNA or antigen was detected in a respiratory specimen collected ≥14 days after completing the primary series of a COVID-19 vaccine with Food and Drug Administration (FDA) approval or emergency use authorization. The COVID-19 case definition, including criteria to distinguish a new case from an existing case, is per the July 2021 update to the national standardized surveillance case definition and national notification for 2019 novel coronavirus disease (COVID-19) (21-ID-01) (https://ndc.services.cdc.gov/case-definitions/coronavirus-disease-2019-2021/). Fully vaccinated persons were those with a completed primary series of 2 doses of the Pfizer-BioNTech or Moderna mRNA vaccine or a single dose of the Janssen vaccine (https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html). A COVID-19 case in an unvaccinated person occurred when the person did not receive any FDA-authorized COVID-19 vaccine doses before the specimen collection date. Cases were excluded in partially vaccinated persons who received at least one FDA-authorized or approved vaccine dose but did not complete a primary series ≥14 days before collection of a respiratory specimen with SARS-CoV-2 RNA or antigen detected. Ascertaining vaccination status for COVID-19 patients through active linkage of case surveillance and immunization information systems typically assumes that cases among persons who are unmatched to the registry are unvaccinated. This analysis represents the combined impact of the Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines, which had different clinical efficacies against confirmed infection. Information on different FDA-authorized and approved COVID-19 vaccine products, including clinical efficacy, is available online. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html
§On August 13, 2021, CDC recommended an additional Pfizer-BioNTech or Moderna primary series dose for persons moderately or severely immunocompromised (https://www.cdc.gov/media/releases/2021/s0813-additional-mRNA-mrna-dose.html). On September 24, 2021, CDC recommended a Pfizer-BioNTech booster dose for certain Pfizer-BioNTech primary series recipients, including all adults aged ≥65 years and persons aged ≥18 years in certain populations and high risk occupational and institutional settings (https://www.cdc.gov/media/releases/2021/p0924-booster-recommendations-.html). On October 21, 2021, CDC recommended a booster dose for adults aged ≥18 years who had received the Janssen vaccine and for Pfizer-BioNTech or Moderna primary series vaccine recipients, including all adults aged ≥65 years and persons aged ≥18 years in certain populations and high risk occupational and institutional settings (https://www.cdc.gov/media/releases/2021/p1021-covid-booster.html). On November 19, 2021, and November 29, 2021, CDC expanded recommendations for booster doses to include all adults aged ≥18 years (https://www.cdc.gov/media/releases/2021/s1119-booster-shots.html, https://www.cdc.gov/media/releases/2021/s1129-booster-recommendations.html).
A COVID-19 case in a fully vaccinated person with a booster dose occurred when a person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of at least 1 additional or booster dose of any COVID-19 vaccine on or after August 13, 2021 (this definition does not distinguish between vaccine recipients who are immunocompromised and are receiving an additional dose versus those who are not immunocompromised and receiving a booster dose).
**A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died, and whose report local health authorities reviewed (e.g., using vital records, public health investigation, or other data sources) to make that determination. Per national guidance, this group should include persons whose death certificate lists COVID-19 disease or SARS-CoV-2 as an underlying cause of death or as a significant condition contributing to death (https://cdn.ymaws.com/www.cste.org/resource/resmgr/pdfs/pdfs2/20211222_interim-guidance.pdf). Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date the patient died.
††National weighted estimates of the proportions of infections attributed to SARS-CoV-2 variants by week are based on analyses of whole-genome sequencing results submitted to or performed by CDC (https://covid.cdc.gov/covid-data-tracker/#variant-proportions). Analysis periods were categorized as April 4–May 29, 2021 (pre-Delta: 0.1%–7% proportion range), May 30–July 3, 2021 (Delta emergence: 14%–69%), July 4–November 27, 2021 (Delta predominance: 81%–99%), and November 28–December 25, 2021, (Omicron emergence: 1%–72%). Other lineages in the analysis period before the Delta transition included Alpha (>50%), Gamma, Epsilon, Iota, Mu, and other lineages.
§§ https://www.census.gov/programs-surveys/popest/data/tables.2019.html
¶¶ https://www.cdc.gov/nchs/data/statnt/statnt20.pdf
***45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56; 42 U.S.C. Sect.241(d); 5 U.S.C.0 Sect.552a; 44 U.S.C. Sect. 3501 et seq.

processing....